Research Center on Life Sciences and Environmental Sciences, Harbin University of Commerce, Harbin, 150076, China.
Institute of Lipid Metabolism and Atherosclerosis, Innovative Drug Research Centre, School of Pharmacy, Weifang Medical University, 7166# Baotongxi Street, Weifang, 261053, Shandong Province, China.
Lipids Health Dis. 2019 Jan 24;18(1):24. doi: 10.1186/s12944-019-0971-1.
N-acetylneuraminic acid (NANA) is the major form of sialic acid in mammals, and the plasma NANA level is increased in patients with cardiovascular diseases. Exogenous supplement of NANA has been demonstrated to reduce hyperlipidaemia and the formation of atherosclerotic lesions; however, the underlying mechanisms have not yet been clarified. The aim of this study is to investigate whether exogenous supplement of NANA improves reverse cholesterol transprot (RCT) in vivo.
Apolipoprotein E-deficient mice fed a high-fat diet were used to investigate the effect of NANA on RCT by [H]-cholesterol-loaded macrophages, and the underlying mechanism was further investigated by various molecular techniques using fenofibrate as a positive control.
Our novel results demonstrated that exogenous supplement of NANA significantly improved [H]-cholesterol transfer from [H]-cholesterol-loaded macrophages to the plasma (an increase of > 42.9%), liver (an increase of 35.8%), and finally to the feces (an increase of 50.4% from 0 to 24 h) for excretion in apolipoprotein E-deficient mice fed a high-fat diet. In addition, NANA up regulated the protein expression of ATP-binding cassette (ABC) G1 and peroxisome proliferator-activated receptor α (PPARα), but not the protein expression of ABCA1and scavenger receptor B type 1 in the liver. Therefore, the underlying mechanism of NANA in improving RCT may be partially due to the elevated protein levels of PPARα and ABCG1.
Exogenous supplement of NANA improves RCT in apolipoprotein E-deficient mice fed a high-fat diet mainly by improving the protein expression of PPARα and ABCG1. These results are helpful in explaining the lipid-lowering effect of NANA.
N-乙酰神经氨酸(NANA)是哺乳动物中唾液酸的主要形式,心血管疾病患者的血浆 NANA 水平升高。外源性补充 NANA 已被证明可降低高脂血症和动脉粥样硬化病变的形成;然而,其潜在机制尚未阐明。本研究旨在探讨外源性补充 NANA 是否能改善体内胆固醇逆向转运(RCT)。
使用载脂蛋白 E 缺陷型小鼠高脂饮食喂养,研究 NANA 对 RCT 的影响,并使用非诺贝特作为阳性对照,进一步用各种分子技术研究其潜在机制。
我们的新结果表明,外源性补充 NANA 可显著改善载脂蛋白 E 缺陷型高脂饮食喂养小鼠 [H]-胆固醇从[H]-胆固醇负载的巨噬细胞向血浆(增加>42.9%)、肝脏(增加 35.8%),最后到粪便(0 到 24 小时增加 50.4%)的转移以排出。此外,NANA 上调了肝脏中 ATP 结合盒(ABC)G1 和过氧化物酶体增殖物激活受体α(PPARα)的蛋白表达,但不影响 ABCA1 和清道夫受体 B 型 1 的蛋白表达。因此,NANA 改善 RCT 的潜在机制可能部分归因于 PPARα 和 ABCG1 蛋白水平的升高。
外源性补充 NANA 主要通过提高 PPARα 和 ABCG1 的蛋白表达来改善载脂蛋白 E 缺陷型高脂饮食喂养小鼠的 RCT。这些结果有助于解释 NANA 的降脂作用。